Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Oil Services ETF
OIH
iShares US Telecommunications ETF
IYZ
4
ProShares Ultra Materials
UYM
5
Energy Select Sector SPDR Fund
XLE
US Stock MarketDetailed Quotes
Jasper Therapeutics (JSPR)
- 1.400
- +0.060+4.48%
Close Feb 19 16:00 ET
- 1.352
- -0.049-3.46%
Pre 08:00 ET
39.18MMarket Cap-0.24P/E (TTM)
1.410High1.310Low130.39KVolume1.350Open1.340Prev Close177.33KTurnover0.56%Turnover RatioLossP/E (Static)27.98MShares7.19052wk High3.39P/B32.89MFloat Cap1.11052wk Low--Dividend TTM23.50MShs Float188.800Historical High--Div Yield TTM7.46%Range %1.110Historical Low1.359Avg Price1Lot Size
JSPR Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
JSPR Orderflow
Unit: --
JSPR Orderflow Trend
IntradayDayWeekMonth
No Data
Jasper Therapeutics (JSPR) News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Jasper Therapeutics Initiated With a Buy at Rodman & Renshaw
RBC Capital Initiates Jasper Therapeutics(JSPR.US) With Hold Rating, Announces Target Price $4
Express News | Jasper Therapeutics Shares Are Trading Lower. The Company Reported Updated Clinical Data From BEACON Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $20
12 Health Care Stocks Moving In Thursday's Intraday Session
Jasper Therapeutics (JSPR) Stock Forum
$Jasper Therapeutics (JSPR.US)$ 🤔 some decent filings recently
1
$Jasper Therapeutics (JSPR.US)$ This hit the scanner thrice today. Taking opportunity to turn this into gold folks. ❤️🙌💯
$Jasper Therapeutics (JSPR.US)$ damn, this company now is under investigation, there goes my investment
$Jasper Therapeutics (JSPR.US)$
Investor Perspective
What stands out most to me at this stage is not just the headline results, but the trajectory.
The OLE data reinforce something important for long-term investors: when efficacy is durable, safety remains favorable over time, and responses are maintained with repeat dosing, it strengthens confidence in the overall development strategy. That kind of consistency is difficult to achieve and meaningful in clinical-stage biotech.
The progress comi...
Investor Perspective
What stands out most to me at this stage is not just the headline results, but the trajectory.
The OLE data reinforce something important for long-term investors: when efficacy is durable, safety remains favorable over time, and responses are maintained with repeat dosing, it strengthens confidence in the overall development strategy. That kind of consistency is difficult to achieve and meaningful in clinical-stage biotech.
The progress comi...
1
$Jasper Therapeutics (JSPR.US)$ Jasper Therapeutics (JSPR.US) shows promising clinical progress with briquilimab in asthma and urticaria, but faces significant financial headwinds including persistent losses and cash burn. While analyst sentiment is optimistic long-term, the stock's high volatility and pre-revenue status make it a high-risk opportunity.
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
Avialevis : been watching this for a while